Clozapine monitoring guidelines for adverse events

A recent study published in the Journal of Clinical Psychiatry, highlights the need of adverse events monitoring when taking clozapine for the treatment of schizophrenia.Actually, there is an established monitoring for agranulocytosis, but a review of 16 studies regarding the use of clozapine revealed that although the incidence rates for diabetic ketoacidosis and gastrointestinal hypomotility are lower, the case-fatality rates of these two adverse events are much higher.

The authors stated that a guideline modification is recommended to include periodic monitoring not only for agranulocytosis, but also for constipation and diabetes.

Be Sociable, Share!